Epidemiology of advanced cutaneous squamous cell carcinoma.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
24
03
2021
accepted:
02
09
2021
pubmed:
1
10
2021
medline:
15
12
2021
entrez:
30
9
2021
Statut:
ppublish
Résumé
Cutaneous invasive squamous cell carcinoma (cSCC) most commonly presents as a typically indolent tumour with five-year cure rates of >90%. Advanced cSCC has been defined as locally advanced or metastatic (locoregional or distant) cSCC. The epidemiological data on advanced cSCC are rare due to underreporting or exclusion of cSCC from national cancer registries. Although the frequency of local recurrence has been reported, there is no clear evidence on the incidence or mortality of locally advanced cSCCs, e.g. locally infiltrating or locally recurrent cSCCs that are not further amenable to curative surgery or radiotherapy. This gap of knowledge on the epidemiology of locally advanced cSCC, highlights the need for standardisation in defining and reporting both locally advanced and metastatic cSCC. Even though metastatic cSCCs are a small part of cSCCs (3%-5%), their aggressive characteristics contribute to significant morbidity, higher mortality and are those likely to require systemic treatments. Locally recurrent and metastatic cSCC may occur more frequently in high-risk cSCCs (up to 35%). The site of metastasis involves in the vast majority the regional lymph nodes, with the head and neck lymph nodes or parotid most commonly affected. Metastasis occurs mostly within 2-3 years of the primary cSCC diagnosis. The knowledge of the incidence and prognosis of advanced cSCC and the risk stratification of patients, who may progress to advanced cSCC, emerge as pressing research areas with important implications for cost-efficiency planning and optimisation of patient care.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-50Informations de copyright
© 2021 European Academy of Dermatology and Venereology.
Références
Stratigos AJ, Garbe C, Dessinioti C et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer 2020; 128: 60-82.
Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol 2018; 78: 237-247.
Nagarajan P, Asgari MM, Green AC et al. Keratinocyte carcinomas: current concepts and future research priorities. Clin Cancer Res 2019; 25: 2379-2391.
Green AC, Olsen CM. Cutaneous squamous cell carcinoma: an epidemiological review. Br J Dermatol 2017; 177: 373-381.
Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol 2012; 106: 811-815.
Ronconi G, Piccinni C, Dondi L et al. Identification of cases and estimate of direct costs of unresectable and advanced cutaneous squamous cell carcinoma: real-world data from a large Italian database. Br J Dermatol 2020; 183: 172-174.
Keohane SG, Botting J, Budny PG et al. British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020. Br J Dermatol 2020; 184: 401-414.
Schmults CB, R. Aasi SZ, Alam M, Andersen JS, Bordeaux J, Bowen GM, Carson W, et al. Squamous cell skin cancer. Version 2.2020- July 14, 2020. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines). Assessed 8 Dec 2020. 2020; https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf.
Stang A, Khil L, Kajuter H et al. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents. J Eur Acad Dermatol Venereol 2019; 33(Suppl 8): 6-10.
Venables ZC, Nijsten T, Wong KF et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study. Br J Dermatol 2019; 181: 474-482.
Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006; 184: 6-10.
Nelson TG, Ashton RE. Low incidence of metastasis and recurrence from cutaneous squamous cell carcinoma found in a UK population: Do we need to adjust our thinking on this rare but potentially fatal event? J Surg Oncol 2017; 116: 783-788.
Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 2013; 149: 541-547.
Joseph MG, Zulueta WP, Kennedy PJ. Squamous cell carcinoma of the skin of the trunk and limbs: the incidence of metastases and their outcome. Aust N Z J Surg 1992; 62: 697-701.
Brantsch KD, Meisner C, Schonfisch B et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713-720.
Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344: 975-983.
Rowe DE, Carroll RJ, Day CL, Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26: 976-990.
Ruiz ES, Karia PS, Besaw R, Schmults CD. Performance of the American joint committee on cancer staging manual, 8th edition vs the Brigham and women's hospital tumor classification system for cutaneous squamous cell carcinoma. JAMA Dermatol 2019; 155: 819-825.
Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. Am J Clin Dermatol 2016; 17: 491-508.
Breuninger H, Black B, Rassner G. Microstaging of squamous cell carcinomas. Am J Clin Pathol 1990; 94: 624-627.
Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 2014; 32: 327-334.
Venables ZC, Autier P, Nijsten T et al. Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England. JAMA Dermatol 2019; 155: 298-306.
Eisemann N, Jansen L, Castro FA et al. Survival with nonmelanoma skin cancer in Germany. Br J Dermatol 2016; 174: 778-785.
Robsahm TE, Helsing P, Veierod MB. Cutaneous squamous cell carcinoma in Norway 1963-2011: increasing incidence and stable mortality. Cancer Med 2015; 4: 472-480.
Brunner M, Veness MJ, Ch'ng S, Elliott M, Clark JR. Distant metastases from cutaneous squamous cell carcinoma-analysis of AJCC stage IV. Head Neck 2013; 35: 72-75.
O'Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 253-261.
Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154: 498-504.
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691.
Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60: 183-189.
Hortlund M, Arroyo Muhr LS, Storm H, Engholm G, Dillner J, Bzhalava D. Cancer risks after solid organ transplantation and after long-term dialysis. Int J Cancer 2017; 140: 1091-1101.
Rizvi SMH, Aagnes B, Holdaas H et al. Long-term change in the risk of skin cancer after organ transplantation: a population-based nationwide cohort study. JAMA Dermatol 2017; 153: 1270-1277.
Madeleine MM, Patel NS, Plasmeijer EI et al. Epidemiology of keratinocyte carcinomas after organ transplantation. Br J Dermatol 2017; 177: 1208-1216.
Lanz J, Bouwes Bavinck JN, Westhuis M et al. Aggressive squamous cell carcinoma in organ transplant recipients. JAMA Dermatol 2019; 155: 66-71.
Rabinovics N, Mizrachi A, Hadar T et al. Cancer of the head and neck region in solid organ transplant recipients. Head Neck 2014; 36: 181-186.
Martinez JC, Otley CC, Stasko T et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003; 139: 301-306.
Lam JKS, Sundaresan P, Gebski V, Veness MJ. Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion. Head Neck 2018; 40: 985-992.
Genders RE, Weijns ME, Dekkers OM, Plasmeijer EI. Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019; 33: 828-841.
Gonzalez JL, Reddy ND, Cunningham K, Silverman R, Madan E, Nguyen BM. Multiple cutaneous squamous cell carcinoma in immunosuppressed vs immunocompetent patients. JAMA Dermatol 2019; 155: 625-627.
Zavos G, Karidis NP, Tsourouflis G et al. Nonmelanoma skin cancer after renal transplantation: a single-center experience in 1736 transplantations. Int J Dermatol 2011; 50: 1496-1500.
Lott DG, Manz R, Koch C, Lorenz RR. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 2010; 90: 683-687.
Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999; 40: 27-34.
Cheng JY, Li FY, Ko CJ, Colegio OR. Cutaneous squamous cell carcinomas in solid organ transplant recipients compared with immunocompetent patients. JAMA Dermatol 2018; 154: 60-66.
Ritter A, Badir S, Mansour M et al. Solid organ transplantation worsens the prognosis of patients with cutaneous squamous cell carcinoma of the head and neck region-Comparison between solid organ transplant recipients and immunocompetent patients. Head Neck 2020; 43: 884-894.
Peat B, Insull P, Ayers R. Risk stratification for metastasis from cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg 2012; 82: 230-233.
Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol 2016; 152: 419-428.
Hillen U, Leiter U, Haase S et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer 2018; 96: 34-43.
Zeng S, Fu L, Zhou P, Ling H. Identifying risk factors for the prognosis of head and neck cutaneous squamous cell carcinoma: A systematic review and meta-analysis. PLoS One 2020; 15: e0239586.
Califano JA, Lydiatt WM, Nehal KS et al. Cutaneous carcinoma of the head and neck. In: Amin MB, S Edge, F Greene, DR Byrd, RK Brookland, MK Washington, JE Gershenwald, CC Compton, KR Hess, DC Sullivan, JM Jessup, JD Brierley, LE Gaspar, RL Schilsky, CM Balch, DP Winchester, EA Asare, M Madera, DM Gress, LR Meyer, eds. AJCC Cancer Staging Manual, 8th edn. Springer, Switzerland; 2017: 171-181.
Jambusaria-Pahlajani A, Kanetsky PA, Karia PS et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol 2013; 149: 402-410.
Union for International Cancer Control. TNM Classification of malignant umours, 8th edn. WILEY Blackwell, Oxford, 2017.
Breuninger H, Brantsch K, Eigentler T, Hafner HM. Comparison and evaluation of the current staging of cutaneous carcinomas. Journal Der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatol: JDDG 2012; 10: 579-586.
Eigentler TK, Leiter U, Hafner HM, Garbe C, Rocken M, Breuninger H. Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study. J Invest Dermatol 2017; 137: 2309-2315.
Conde-Ferreiros A, Corchete LA, Puebla-Tornero L et al. Definition of prognostic subgroups in the T3 stage of the eighth edition of the American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Tentative T3 stage subclassification. J Am Acad Dermatol. 2021; 85: P1168-1177.
Roscher I, Falk RS, Vos L et al. Validating 4 staging systems for cutaneous squamous cell carcinoma using population-based data: a nested case-control study. JAMA Dermatol 2018; 154: 428-434.
Canueto J, Burguillo J, Moyano-Bueno D et al. Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice. J Am Acad Dermatol 2019; 80: 106-113 e102.
Puebla-Tornero L, Corchete-Sanchez LA, Conde-Ferreiros A et al. Performance of Salamanca refinement of the T3-AJCC8 versus the Brigham and Women's Hospital and Tubingen alternative staging systems for high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol 2021; 84: 938-945.
Karia PS, Morgan FC, Ruiz ES, Schmults CD. Clinical and incidental perineural invasion of cutaneous squamous cell carcinoma: a systematic review and pooled analysis of outcomes data. JAMA Dermatol 2017; 153: 781-788.
Conde-Ferreiros A, Corchete LA, Jaka A et al. Patterns of incidental perineural invasion and prognosis in cutaneous squamous cell carcinoma: a multicenter, retrospective cohort study. J Am Acad Dermatol 2020; 84: 1708-1712.
Manyam BV, Garsa AA, Chin RI et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer 2017; 123: 2054-2060.
Tam S, Yao C, Amit M et al. Association of immunosuppression with outcomes of patients with cutaneous squamous cell carcinoma of the head and neck. JAMA Otolaryngol Head Neck Surg 2020; 146: 128-135.
Elghouche AN, Pflum ZE, Schmalbach CE. Immunosuppression impact on head and neck cutaneous squamous cell carcinoma: a systematic review with meta-analysis. Otolaryngol Head Neck Surg 2019; 160: 439-446.
Inman GJ, Wang J, Nagano A et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nat Commun 2018; 9: 3667.
Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Schmults CD. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol 2014; 150: 280-287.
Breuninger H, Schaumburg-Lever G, Holzschuh J, Horny HP. Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer 1997; 79: 915-919.
Migden MR, Rischin D, Schmults CD et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379: 341-351.
Migden MR, Khushalani NI, Chang ALS et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020; 21: 294-305.
Hughes BGM, Munoz-Couselo E, Mortier L et al. Phase 2 study of pembrolizumab for locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma: KEYNOTE-629. Abstract CT006. Presented April 10, 2021.Available at: https://www.abstractsonline.com/pp8/#!/9325/presentation/5137. Assessed June 19, 2021. AACR Annual Virtual Meeting 2021.
European Medicines Agency. Libtayo. Summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf Access date: 17 July 2019.